SAVOXEPIN MESYLATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C25H26N2O.CH4O3S
Molecular Weight	466.592
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CS(O)(=O)=O.N#CC1=CC2=C(OC3=C(C=CC=C3)C4=C2CCN(CC5CCCC5)CC4)C=C1

InChI

InChIKey=PDYLRPIUJQGVNY-UHFFFAOYSA-N

InChI=1S/C25H26N2O.CH4O3S/c26-16-19-9-10-25-23(15-19)21-12-14-27(17-18-5-1-2-6-18)13-11-20(21)22-7-3-4-8-24(22)28-25;1-5(2,3)4/h3-4,7-10,15,18H,1-2,5-6,11-14,17H2;1H3,(H,2,3,4)

HIDE SMILES / InChI

Molecular Formula	C25H26N2O
Molecular Weight	370.4867
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	CH4O3S
Molecular Weight	96.106
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2565583 | https://www.ncbi.nlm.nih.gov/pubmed/12111340 | https://adisinsight.springer.com/drugs/800000647

Savoxepine (also known as cipazoxapine), a tetracyclic compound, possesses a potent neuroleptic-like effects. This compound acts via dopamine D(2)-receptor blockade. Savoxepine was studied in phase II clinical trials in Europe for the treatment of patients with psychotic disorders; however, these studied were discontinued.

Originator

Approval Year

PubMed

Title	Date	PubMed
Neuroleptic profile of cipazoxapine (Savoxepine), a new tetracyclic dopamine antagonist: clinical validation of the hippocampus versus striatum ratio model of dopamine receptors in animals. A preliminary report.	1987 May	2885867
Savoxepine: striatal dopamine-D2 receptor occupancy in human volunteers measured using positron emission tomography (PET).	1993	8095895
Savoxepine fails to selectively influence glucose metabolism in the rat limbic system.	1994 Mar	7838920
Direct microtitre plate radioimmunoassay of savoxepine in unextracted plasma.	1996 Feb	8926305

Patents

Sample Use Guides

In Vivo Use Guide

In an open pilot-study 18 patients suffering from acute schizophrenic psychoses or paranoid syndromes were treated with savoxepine in an individually adapted dose range from 0.50 to 10 mg per day

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:35:33 GMT 2023` Edited by `admin` on `Fri Dec 15 15:35:33 GMT 2023`
Record UNII	E4T7MA518S
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SAVOXEPIN MESYLATE

Common Name

English

1H-DIBENZ(2,3:6,7)OXEPINO(4,5-D)AZEPINE-7-CARBONITRILE, 3-(CYCLOPENTYLMETHYL)-2,3,4,5-TETRAHYDRO-, METHANESULFONATE (1:1)

Systematic Name

English

SAVOXEPIN MESILATE

Common Name

English

SAVOXEPINE MESYLATE

Common Name

English

CGP-19486A

Code

English

CGP 19486A

Code

English

1H-DIBENZ(2,3:6,7)OXEPINO(4,5-D)AZEPINE-7-CARBONITRILE, 3-(CYCLOPENTYLMETHYL)-2,3,4,5-TETRAHYDRO-, MONOMETHANESULFONATE

Systematic Name

English

Code System Code Type Description

CAS

79262-47-8